TY - JOUR
T1 - Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy
AU - Zhao, Yiming
AU - Fay, François
AU - Hak, Sjoerd
AU - Manuel Perez-Aguilar, Jose
AU - Sanchez-Gaytan, Brenda L.
AU - Goode, Brandon
AU - Duivenvoorden, Raphaël
AU - de Lange Davies, Catharina
AU - Bjørkøy, Astrid
AU - Weinstein, Harel
AU - Fayad, Zahi A.
AU - Pérez-Medina, Carlos
AU - Mulder, Willem J. M.
PY - 2016
Y1 - 2016
N2 - A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery of anti-tumour agents. The drug-carrier association after intravenous administration is essential for efficient drug delivery to the tumour. However, a large number of currently available nanocarriers are self-assembled nanoparticles whose drug-loading stability is critically affected by the in vivo environment. Here we used in vivo FRET imaging to systematically investigate how drug-carrier compatibility affects drug release in a tumour mouse model. We found the drug's hydrophobicity and miscibility with the nanoparticles are two independent key parameters that determine its accumulation in the tumour. Next, we applied these findings to improve chemotherapeutic delivery by augmenting the parent drug's compatibility; as a result, we achieved better antitumour efficacy. Our results help elucidate nanomedicines' in vivo fate and provide guidelines for efficient drug delivery
AB - A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery of anti-tumour agents. The drug-carrier association after intravenous administration is essential for efficient drug delivery to the tumour. However, a large number of currently available nanocarriers are self-assembled nanoparticles whose drug-loading stability is critically affected by the in vivo environment. Here we used in vivo FRET imaging to systematically investigate how drug-carrier compatibility affects drug release in a tumour mouse model. We found the drug's hydrophobicity and miscibility with the nanoparticles are two independent key parameters that determine its accumulation in the tumour. Next, we applied these findings to improve chemotherapeutic delivery by augmenting the parent drug's compatibility; as a result, we achieved better antitumour efficacy. Our results help elucidate nanomedicines' in vivo fate and provide guidelines for efficient drug delivery
U2 - https://doi.org/10.1038/ncomms11221
DO - https://doi.org/10.1038/ncomms11221
M3 - Article
C2 - 27071376
SN - 2041-1723
VL - 7
SP - 11221
JO - Nature communications
JF - Nature communications
ER -